Antiemetics: American Society of Clinical Oncology focused guideline update

Journal of Clinical Oncology

Volumn 34, Issue 4, 2016, Pages 381-386

  Hesketh, Paul J ^a   Bohlke, Kari ^b   Lyman, Gary H ^e   Basch, Ethan ^f   Chesney, Maurice ^g   Clark Snow, Rebecca Anne ^h   Danso, Michael A ^c,d   Jordan, Karin ⁱ   Somerfield, Mark R ^b   Kris, Mark G ^j  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c Virginia Oncology Associates   (United States)

^d Virginia Oncology Associates   (United States)

^e USA   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g Martin Luther University Halle Wittenberg ^*  (United States)

^h UNIVERSITY OF KANSAS CANCER CENTER   (United States)

ⁱ MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; APREPITANT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; FOSAPREPITANT; GRANISETRON; IRINOTECAN; NETUPITANT PLUS PALONOSETRON; ONDANSETRON; OXALIPLATIN; PALONOSETRON; RAMOSETRON; TROPISETRON; ANTINEOPLASTIC AGENT;

ACUTE PSYCHOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; TREATMENT INDICATION; TREATMENT RESPONSE; CHEMICALLY INDUCED; NAUSEA; PROCEDURES; STANDARDS; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NAUSEA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 84955491114     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.3635     Document Type: Article

References (7)

1. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines - American Society of Clinical Oncology. J Clin Oncol 17:2971-2994, 1999
2. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006
3. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-4198, 2011
4. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
5. Aapro M, Rugo H, Rossi G, et al: A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328-1333, 2014
6. Gralla RJ, Bosnjak SM, Hontsa A, et al: A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333-1339, 2014
7. Hesketh PJ, Rossi G, Rizzi G, et al: Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study. Ann Oncol 25:1340-1346, 2014